^
    Back
    Association details:
    Biomarker:KIT exon 11 mutation
    Cancer:Melanoma
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    ACS Publications
    Title:

    A phase II trial of dasatinib in advanced melanoma

    Excerpt:
    An exon 11 deletion mutation was found in one other patient who did not respond to dasatinib.
    DOI:
    10.1002/cncr.25766